ctDNA insights from KEYNOTE-B15 by #DrJonathanChatzkel: perioperative EV + Pembro vs Gem/Cis in cis-eligible MIBC. ctDNA clearance 82.1% vs 66.7%.

Toni Choueiri, MD· @DrChoueiri · X·2026-10-23 20:55· 2 天前评分90

正文 · 原文

ctDNA insights from KEYNOTE-B15 by #DrJonathanChatzkel: perioperative EV + Pembro vs Gem/Cis in cis-eligible MIBC. ctDNA clearance 82.1% vs 66.7%.
Post-surgery ctDNA+ 4.8% vs 13.5%.
EFS benefit with EV/Pembro across baseline ctDNA strata, exploratory ctDNA+ HR 0.54.

#ESMO26 #BladderCancer @myESMO @OncoAlert

1030 浏览 · 21 赞 · 14 转发 · 0 回复

会议摘要

4734O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin

https://esmocongress.esmo.org

NCT04700124NCT04700124按 - **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304) 对上

- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)

https://esmocongress.esmo.org

来源：Toni Choueiri, MD · x.com